(NASDAQ: TKNO) Alpha Teknova's forecast annual revenue growth rate of 5.88% is forecast to beat the US Drug Manufacturers - Specialty & Generic industry's average forecast revenue growth rate of 0.59%, and while it is not forecast to beat the US market's average forecast revenue growth rate of 55.62%.
Alpha Teknova's revenue in 2025 is $38,250,000.On average, 1 Wall Street analysts forecast TKNO's revenue for 2025 to be $2,164,352,805, with the lowest TKNO revenue forecast at $2,164,352,805, and the highest TKNO revenue forecast at $2,164,352,805.
In 2026, TKNO is forecast to generate $2,490,341,746 in revenue, with the lowest revenue forecast at $2,490,341,746 and the highest revenue forecast at $2,490,341,746.